A Phase 2 Proof-of-Concept Study of CSI-Glucagon (Continuous Subcutaneous Glucagon Infusion) to Prevent Hypoglycemia With Lower Intravenous Glucose Infusion Rates in Children up to One Year of Age With Congenital Hyperinsulinism

Trial Profile

A Phase 2 Proof-of-Concept Study of CSI-Glucagon (Continuous Subcutaneous Glucagon Infusion) to Prevent Hypoglycemia With Lower Intravenous Glucose Infusion Rates in Children up to One Year of Age With Congenital Hyperinsulinism

Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Oct 2017

At a glance

  • Drugs Glucagon (Primary)
  • Indications Hypoglycaemia
  • Focus Therapeutic Use
  • Sponsors XERIS Pharmaceuticals
  • Most Recent Events

    • 13 Oct 2017 Planned End Date changed from 1 Dec 2017 to 1 Jun 2018.
    • 13 Oct 2017 Planned primary completion date changed from 1 Sep 2017 to 1 May 2018.
    • 20 Oct 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top